In its relatively short tenure thus-far, the exploding marijuana market has birthed numerous business opportunities for corporations and pharmaceuticals who see revenue-generating opportunities as a result of loosened medical marijuana laws. One of the sturdiest niches within this industry is edible cannabis-based medicines, driven by a growing number of patients worldwide who benefit from the therapeutic properties of cannabinoids.
The most common oral administration of cannabinoids is through edibles such as cookies, brownies, butter, tea, cakes and lozenges. Countless companies are exploring this market, opening up bakeries and dispensaries offering a wide variety of cannabis edibles.
But because of their “confectionary” packaging, the potency of edibles made from marijuana is unknown and often underestimated. Cannabis-infused edibles usually contain high doses of cannabinoids, which may cause undesirable side effects such as dizziness, anxiety and dissociation. While the oral administration of cannabis has the longest therapeutic window (4-8 hours), the psychoactive side effects are often a deterrent for individuals seeking therapeutic benefit rather than a recreational high.
Cannabics Pharmaceuticals years ago recognized this unmet need for an oral formulation with higher bioavailabity and a lessened peak of psychoactive effect. In fact, the company was founded in 2012 by a team of researchers in the fields of molecular biology, cancer research and pharmacology who embarked upon a mission to formulate a new type of oral capsule with a longer and plateaued therapeutic window and lower psychoactive outcome.
The company’s flagship product is Cannabics SR, an IP-pending medical cannabis capsule designed specifically for cancer patients as a palliative care treatment. Free of any artificial additives or chemical substances, the capsule contains a pure concentrate of cannabinoids derived from select cannabis strains, embedded in a sophisticated and advanced formulation. In observational studies, the Cananbics SR capsules provided beneficial therapeutic effects for 10-12 hours upon a single oral administration. Cannabics SR capsules have been used by certified patients in Israel during the last year, and received highly positive and supportive reviews from both patients and physicians.
Cannabics Pharmaceuticals is now preparing to launch its line of SR products in eligible states of the U.S. and EU markets under existing medical cannabis regulations. As part of its overarching mission, the company recently secured an IP licensing and collaboration agreement with Spain-based Kalapa Holding, which will manufacture and distribute Cannabics SR medical cannabis products to certified patients in the Spanish market.
Through its research and development facility in Israel, Cannabics Pharmaceuticals continues to develop its pipeline of advanced cannabinoid-based therapies, leveraging collaborations with major medical centers in Israel and momentum from its new partnership with Kalapa Holding in Europe.
While the U.S. FDA has yet to approve even basic private research relating to cannabis, much less FDA approval for cannabis-based edible products for medicinal use, the environment is quite different in Israel. Within the Israeli Ministry of Health, there is a stand-alone agency, the Israeli Medical Cannabis Agency, (IMCA), which just last month granted Cannabics Pharmaceuticals a government license to launch their advanced scientific R&D program at their new state of the art laboratory for controlled & exclusive Cannabinoid Research. With this government license and new laboratory, Cannabics Pharmaceuticals is now set to conduct high level scientific and medical research for the identification of novel cannabinoid based therapies, as well as formal and controlled clinical studies in order to gauge and authenticate the true medical benefits of these therapies. An obvious long-term goal for these R&D programs would be the eventual FDA approval and registration as Rx pharmaceuticals of the natural cannabinoid based therapies developed by the company – a goal that has not yet been achieved by any pharmaceutical company in the world.
Unlike most current producers of edible cannabis products, Cannabis Pharmaceuticals is focusing a substantial amount of its energies and funds not only in generating sales, but also in the actual science of cannabinoids, with the goal of developing novel cannabinoid based therapies for various debilitating ailments. Given the penetrating research to date performed by the company, along with their new R&D lab, IMCA license and upcoming clinical studies, it appears that Cannabics Pharmaceuticals may well reach its professed goal of “being a leading pioneer of scientifically proven medical cannabinoid pharmacology”, and much earlier than they had even hoped for.
For more information, visit www.cannabics.com
Let us hear your thoughts: Cannabics Pharmaceuticals, Inc. Message Board
